General considerations of immunosuppressive therapies - Efficacy versus toxicity

Transplantation Proceedings

Volumn 33, Issue 3 SUPPL. 1, 2001, Pages S2-S3

  Helderman, J H ^a,b  

^a Vanderbilt University Transplant Center   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZATHIOPRINE; CYCLOSPORIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PROTEIN INHIBITOR; RAPAMYCIN; STEROID; TACROLIMUS;

ANEMIA; CANDIDA; CLINICAL TRIAL; CYTOMEGALOVIRUS; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GRAFT REJECTION; GRAFT SURVIVAL; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LEUKOPENIA; NAUSEA; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PURINE SYNTHESIS; SHORT SURVEY; THROMBOCYTOPENIA; TOXICITY; VOMITING;

CLINICAL TRIALS, PHASE III; GASTROINTESTINAL DISEASES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; TREATMENT OUTCOME;

EID: 0034996162     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(01)02062-0     Document Type: Article

References (7)

1. US Renal Transplant Mycophenolate Mofetil Study Group: Am J Kidney Dis 34:296, 1999
2. European Mycophenolate Mofetil Cooperative Study Group: Lancet 345:1321, 1995
3. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: Transplantation 61:1029, 1996
4. Ojo AO, Meier-Kriesche H-V, Hanson JA, et al: Transplantation 69:2405, 2000
5. Goral S, Helderman JH: Transplantation 69:2239, 2000
6. Fujihara CK, Malheiros DM, Zatz R, et al: Kidney Int 54:1510, 1998
7. Muller V, Hamar P, Szabo A, et al: Transplant Proc 30:982, 1998